(Q28143533)

24 May 2017

main subject

gram-positive bacteria

0 references

2

David P. Figgitt

1 reference

24 May 2017

author name string

H M Lamb

1

0 references

D P Figgitt

2

0 references

D Faulds

3

0 references

Harriet M. Lamb

1

1 reference

24 May 2017

Diana Faulds

3

1 reference

24 May 2017

language of work or name

English

0 references

publication date

December 1999

0 references

1999

1 reference

24 May 2017

1 reference

24 May 2017

volume

58

1 reference

24 May 2017

issue

6

1 reference

24 May 2017

page(s)

1061-97

0 references

1061-1097

1 reference

Antimicrobial susceptibility of viridans group streptococci

24 May 2017

cites work

1 reference

12 December 2020

Medium and supplement effects on the antimicrobial activity of quinupristin/dalfopristin tested by agar dilution and Etest methods

1 reference

12 December 2020

Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients.

1 reference

12 December 2020

Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997)

1 reference

12 December 2020

Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.

1 reference

12 December 2020

In-vitro activities of quinupristin/dalfopristin and other anti-staphylococcal agents against methicillin-resistant strains of Staphylococcus aureus isolated over a 16-year period.

1 reference

12 December 2020

Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aure

1 reference

12 December 2020

[Susceptibilities of Enterococcus faecium, PRSP and MRSA to RP59500 and their correlations with those to other drugs]

1 reference

12 December 2020

Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. Sentry Participants Group

1 reference

12 December 2020

Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination

1 reference

12 December 2020

[Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].

1 reference

12 December 2020

Comparative activity of eighteen antimicrobial agents against anaerobic bacteria isolated in South Africa

1 reference

12 December 2020

The streptogramin antibiotics: update on their mechanism of action.

1 reference

12 December 2020

In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates

1 reference

12 December 2020

Vancomycin-resistant enterococci osteomyelitis in the foot. A case report

1 reference

12 December 2020

Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates

1 reference

12 December 2020

Quinupristin/dalfopristin: a review of its activity in experimental animal models of infection

1 reference

12 December 2020

Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients.

1 reference

12 December 2020

In-vitro bactericidal activity of quinupristin/dalfopristin against adherent Staphylococcus aureus

1 reference

12 December 2020

Successful treatment of infection due to Mycoplasma hominis with streptogramins in a renal transplant patient: case report and review

1 reference

12 December 2020

Comparative activity of quinupristin/dalfopristin and RPR 106972 and the effect of medium on in-vitro test results.

1 reference

12 December 2020

Streptogramins: an answer to antibiotic resistance in gram-positive bacteria

1 reference

12 December 2020

Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods.

1 reference

12 December 2020

Susceptibility to RPR 106,972, quinupristin/dalfopristin and erythromycin among recent clinical isolates of enterococci, staphylococci and streptococci from North American medical centres

1 reference

12 December 2020

RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci

1 reference

12 December 2020

Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities

1 reference

12 December 2020

Management of infections due to resistant enterococci: a review of therapeutic options

1 reference

12 December 2020

In-vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci

1 reference

12 December 2020

In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci

1 reference

12 December 2020

Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies

1 reference

12 December 2020

Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin.

1 reference

12 December 2020

In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens

1 reference

12 December 2020

Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci

1 reference

12 December 2020

Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin

1 reference

12 December 2020

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

1 reference

12 December 2020

In vitro activity of an orally administered streptogramin (RPR 106,972) compared to quinupristin/dalfopristin and erythromycin

1 reference

12 December 2020

Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)

1 reference

12 December 2020

Activity of quinupristin/dalfopristin against Streptococcus pneumoniae in vitro and in vivo in the rabbit model of experimental meningitis

1 reference

12 December 2020

In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods

1 reference

12 December 2020

The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group

1 reference

12 December 2020

Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing

1 reference

12 December 2020

Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp

1 reference

12 December 2020

Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort

1 reference

12 December 2020

Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.

1 reference

12 December 2020

Quinupristin/dalfopristin in neonatal Enterococcus faecium meningitis

1 reference

12 December 2020

Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains

1 reference

12 December 2020

In-vitro activity of RP 59500, a new synergic antibacterial agent, against Legionella spp

1 reference

12 December 2020

Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia

1 reference

12 December 2020

Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium

1 reference

12 December 2020

Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium

1 reference

12 December 2020

In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, or RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant enterococci.

1 reference

12 December 2020

Time-kill kinetics of quinupristin/dalfopristin on Staphylococcus aureus with and without a raised MBC evaluated by two methods.

1 reference

12 December 2020

Association between quinupristin/dalfopristin resistance in glycopeptide-resistant Enterococcus faecium and the use of additives in animal feed.

1 reference

12 December 2020

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

1 reference

12 December 2020

Multidrug resistance--a sign of the times.

1 reference

12 December 2020

Vancomycin-resistant enterococci: the clinical effect of a common nosocomial pathogen.

1 reference

12 December 2020

Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis

1 reference

12 December 2020

In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004

1 reference

12 December 2020

In vitro activity of quinupristin/dalfopristin against clinical isolates of common gram-positive bacteria in Taiwan.

1 reference

12 December 2020

Resistance to glycopeptides in enterococci

1 reference

12 December 2020

In-vitro antibacterial activity of RP 59500, a semisynthetic streptogramin, against Streptococcus pneumoniae

1 reference

12 December 2020

Comparative in-vitro activity of RP 59500

1 reference

12 December 2020

MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible

1 reference

12 December 2020

Therapy with RP 59500 (quinupristin/dalfopristin) for prosthetic valve endocarditis due to enterococci with VanA/VanB resistance patterns

1 reference

12 December 2020

Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500

1 reference

12 December 2020

In vitro activity of quinupristin/dalfopristin (RP 59500) against a large collection of infrequently isolated or tested species

1 reference

12 December 2020

Selection of Enterococcus faecium strains with stable and unstable resistance to the streptogramin RP 59500 using stepwise in vitro exposure

1 reference

12 December 2020

Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology

1 reference

12 December 2020

Quinupristin/dalfopristin (RP 59500) therapy for vancomycin-resistant Enterococcus faecium aortic graft infection: case report

1 reference

12 December 2020

Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study

1 reference

12 December 2020

Comparative in vitro activity of vancomycin and other antimicrobial agents against methicillin-resistant staphylococcus aureus and enterococcus faecium in the Tohoku district of Japan

1 reference

12 December 2020

Treatment of vancomycin-resistant Enterococcus faecium infections

1 reference

12 December 2020

In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci

1 reference

12 December 2020

Simultaneous high-performance liquid chromatographic determination of quinupristin, dalfopristin and their main metabolites in human plasma

1 reference

12 December 2020

In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates

1 reference

12 December 2020

Epidemiology of methicillin-resistant Staphylococcus aureus

1 reference

12 December 2020

In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and Enterococci

1 reference

12 December 2020

Activity of quinupristin/dalfopristin and its components against Haemophilus influenzae

1 reference

12 December 2020

In-vitro activity of 29 antimicrobial agents against penicillin-resistant and -intermediate isolates of Streptococcus pneumoniae

1 reference

12 December 2020

Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium

1 reference

12 December 2020

A collaborative study of the in-vitro sensitivity to RP 59500 of bacteria isolated in seven hospitals in France

1 reference

12 December 2020

The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans

1 reference

12 December 2020

Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxa

1 reference

12 December 2020

Persistence of vancomycin-resistant Enterococcus faecium gastrointestinal tract colonization in antibiotic-treated mice

1 reference

12 December 2020

In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms

1 reference

12 December 2020

Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia

1 reference

12 December 2020

In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci

1 reference

12 December 2020

Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin

1 reference

12 December 2020

Severe reversible reticulocytopenic anemia associated with quinupristin/dalfopristin RP59500 therapy

1 reference

12 December 2020

In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections

1 reference

12 December 2020

In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria

1 reference

12 December 2020

Post-antibiotic effects of RP 59500 with Staphylococcus aureus

1 reference

12 December 2020

The in-vitro activity of linezolid (U-100766) and tentative breakpoints

1 reference

12 December 2020

Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.

1 reference

12 December 2020

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect

1 reference

12 December 2020

Life-threatening infection with multiresistant Staphylococcus epidermidis in a patient with end-stage renal disease: cure with chloramphenicol and quinupristin/dalfopristin (RP 59500)

1 reference

12 December 2020

Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam

1 reference

12 December 2020

Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis

1 reference

12 December 2020

A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500

1 reference

12 December 2020

In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis

1 reference

12 December 2020

Antibiotic usage in animals: impact on bacterial resistance and public health

1 reference

12 December 2020

Vancomycin-resistant Enterococcus faecium shunt infection in an infant: an antibiotic cure

1 reference

12 December 2020

In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant Streptococcus pneumoniae.

1 reference

12 December 2020

Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus

1 reference

12 December 2020

Activity of quinupristin/dalfopristin against Staphylococcus epidermidis in biofilms: a comparison with ciprofloxacin

1 reference

12 December 2020

In-vitro antibiotic susceptibility and molecular analysis of anaerobic bacteria isolated in Cape Town, South Africa.

1 reference

12 December 2020

In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium

1 reference

12 December 2020

The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan

1 reference

12 December 2020

Occurrence and epidemiology of resistance to virginiamycin and streptogramins

1 reference

12 December 2020

Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species

1 reference

12 December 2020

In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci

1 reference

12 December 2020

In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis

1 reference

12 December 2020

In vitro activities of quinupristin-dalfopristin and the streptogramin RPR 106972 against Mycoplasma pneumoniae.

1 reference

12 December 2020

In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies

1 reference

12 December 2020

Provisional quality control parameters and interpretive criteria for testing susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to quinupristin/dalfopristin (RP59500). Antimicrobial Testing Quality Control Group

1 reference

12 December 2020

Susceptibility of penicillin-resistant and penicillin-susceptible Streptococcus pneumoniae to newer antimicrobial agents

1 reference

12 December 2020

The postantibiotic effect of RP 59500 on Staphylococcus aureus including strains with a raised MBC

1 reference

12 December 2020

Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin).

1 reference

12 December 2020

In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients

1 reference

12 December 2020

RP 59500: a proposed mechanism for its bactericidal activity

1 reference

12 December 2020

Comparative in-vitro activity of RP 59500 against clinical bacterial isolates

1 reference

12 December 2020

Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics.

1 reference

12 December 2020

Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests

1 reference

12 December 2020

Quinupristin/dalfopristin attenuates the inflammatory response and reduces the concentration of neuron-specific enolase in the cerebrospinal fluid of rabbits with experimental Streptococcus pneumoniae meningitis

1 reference

12 December 2020

The in-vitro activity of a new semi-synthetic streptogramin compound, RP 59500, against staphylococci and respiratory pathogens

1 reference

12 December 2020

Staphylococcus epidermidis endocarditis treated with RP 59500 (quinapristin/dalfopristin)

1 reference

12 December 2020

Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci

1 reference

12 December 2020

In-vitro activity of RP 59500, a new semisynthetic injectable pristinamycin against staphylococci

1 reference

12 December 2020

Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.

1 reference

12 December 2020

Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms.

1 reference

12 December 2020

Minimal inhibitory concentrations and minimal bactericidal concentrations of quinupristin/dalfopristin against clinical isolates of Corynebacterium jeikeium and Listeria monocytogenes

1 reference

12 December 2020

Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci

1 reference

12 December 2020

RP59500 (Quinupristin/dalfopristin): three case reports of its use in infection due to Enterococcus faecium

1 reference

12 December 2020

The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination

1 reference

12 December 2020

The in-vitro activity of RP 59500 against gram-positive cocci

1 reference

12 December 2020

Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with [...]

1 reference

12 December 2020

Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program

1 reference

12 December 2020

In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi.

1 reference

12 December 2020

Interaction between quinupristin/dalfopristin and cyclosporine

1 reference

12 December 2020

Vancomycin-resistant enterococci (VRE) colonization of high-risk patients in tertiary care Canadian hospitals. Canadian VRE Surveillance Group.

1 reference

12 December 2020

Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.

1 reference

12 December 2020

Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection

1 reference

12 December 2020

In vitro susceptibilities of aerobic and facultative non-spore-forming gram-positive bacilli to HMR 3647 (RU 66647) and 14 other antimicrobials.

1 reference

12 December 2020

Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases

1 reference

12 December 2020

Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria

1 reference

12 December 2020

In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria

1 reference

12 December 2020

Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy

1 reference

12 December 2020

Post-antibiotic effect of the new streptogramin RP 59500.

1 reference

12 December 2020

Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance

1 reference

12 December 2020

Susceptibility of anaerobic bacteria to the new streptogramin RP 59500 in vitro

1 reference

12 December 2020

In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group

1 reference

12 December 2020

In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500

1 reference

12 December 2020

10.2165/00003495-199958060-00008

Identifiers

DOI

1 reference